2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
1998
Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?
Laine L, Hopkins R, Girardi L. Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated? The American Journal Of Gastroenterology 1998, 93: 1409. PMID: 9732917, DOI: 10.1111/j.1572-0241.1998.452_a.x.Peer-Reviewed Original ResearchConceptsH. pylori eradicationH. pylori therapyUlcer recurrencePylori eradicationPylori therapyH. pylori cureNon-NSAID ulcersCompletion of therapyHelicobacter pylori therapyUse of NSAIDsDuodenal ulcer patientsNorth American trialsUlcer recurrence rateHigh methodological qualityEndoscopic biopsy testsReview of abstractsEndoscopic followUlcer patientsDuodenal ulcerRelevant trialsRecurrence rateStudy inclusionOdds ratioCommon odds ratioMethodological quality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply